ORPHA:273
Steinert myotonic dystrophy
Also known as: Myotonic dystrophy type 1 · Steinert disease
Publications
17,162
96.5th percentile
Trials
45
Interventional, condition-specific
Researchers
1,237
Distinct authors in sample
Gene link
DMPK
Definitive
Readiness
6/6
Stages with a signal
Clinical definition (Orphanet)
A rare genetic multi-system disorder characterized by a wide range of muscle-related manifestations (muscle weakness, myotonia, early onset cataracts (before age 50) and systemic manifestations (cerebral, endocrine, cardiac, gastrointestinal tract, uterus, skin and immunologic involvement) that vary depending on the age of onset. The very wide clinical spectrum ranges from lethal presentations in infancy to mild, late-onset disease.
How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008056
- OMIM:160900
- UMLS:C3250443
- NCIT:C84679
Additional Mondo synonyms (8)
DM1 · DMPK myotonic dystrophy · MD1 · Steinert myotonic dystrophy syndrome · Steinert syndrome · dystrophia myotonica · myotonic dystrophy caused by mutation in DMPK · myotonic dystrophy type 1
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
6/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — DMPK
- LiteraturePresent
17,162 matched papers (8,431 in last 10 years) Source
- Phenotype characterisedPresent
165 HPO annotations (e.g. Abnormally slow thought process; Premature birth; Speech apraxia) Source
- Animal modelPresent
18 genotype models (Mus musculus) Source
- Orphan designationPresent
1 FDA designation (1 FDA orphan-indication approval) — e.g. Tideglusib Source
- Interventional trialPresent
45 matched on ClinicalTrials.gov (16 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (DMPK).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
165
Associated phenotypes · MONDO:0008056
- Abnormally slow thought process
- Premature birth
- Speech apraxia
- Bundle branch block
- Cataract
Showing 5 of 165 — open Monarch for the full list.
Animal models (Monarch / Alliance)
18
Model associations linked to this Mondo ID
- Dmpktm1Rdd/Dmpktm1Rdd [background:] involves: 129S2/SvPas * C57BL/6J·MGI:3613697·Mus musculus
- Tg(HSA*LR)41Cath/? [background:] involves: FVB/N·MGI:3763919·Mus musculus
- Tg(Ckm-CUGBP1)1039Coop/0 [background:] FVB-Tg(Ckm-CUGBP1)1039Coop·MGI:5427874·Mus musculus
- Tg(Myh6-rtTA)8585Jam/0 Tg(tetO-CUGBP1)3413Coop/0 [background:] involves: FVB * FVB/N * FVB/NTac·MGI:4438035·Mus musculus
- Tg(HSA*LR)32bCath/? [background:] involves: FVB/N·MGI:3763922·Mus musculus
- Tg(DMWD,DMPK*,SIX5)328Ggo/Tg(DMWD,DMPK*,SIX5)328Ggo [background:] involves: C57BL/6 * DBA/2·MGI:5523468·Mus musculus
- Dmpktm1Rdd/Dmpk+ [background:] involves: 129S2/SvPas * C57BL/6J·MGI:3613741·Mus musculus
- Tg(DM15)26Bew/0 [background:] involves: FVB·MGI:3054527·Mus musculus
- Tg(HSA*LR)20bCath/? [background:] involves: FVB/N·MGI:3763917·Mus musculus
- Tg(HSA*LR)20aCath/? [background:] involves: FVB/N·MGI:3763920·Mus musculus
- Tg(HSA*LR)32aCath/? [background:] involves: FVB/N·MGI:3763921·Mus musculus
- Tg(ACTA1-cre/ERT2)97.16Mtz/0 Tg(CAG-DMPK*)1323Coop/0 [background:] involves: FVB·MGI:5426828·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
1
Designation · 1 with FDA orphan-indication approval
- FDA TideglusibMyotonic Dystrophy DM1 · 2017-06-19 · Not FDA Approved for Orphan Indication
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
12
Drugs / clinical candidates · MONDO_0008056
- DELPACIBART ETEDESIRAN·phase 3
- METFORMIN·phase 3
- MEXILETINE·phase 3
- ZELECIMENT BASIVARSEN·phase 3
- PITOLISANT·phase 2
- AMLODIPINE·phase 1
- RANOLAZINE·phase 1
- AMITRIPTYLINE HYDROCHLORIDE·phase 1 2
- MECASERMIN·phase 1 2
- METHYLPHENIDATE·phase 2 3
- RINFABATE·phase 1 2
- TIDEGLUSIB·phase 2 3
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
17,162
17,162 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
17,162 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
8,431 in the last 10 years · medium confidence · 96.5th percentile (publications denominator)
Phrase hits: 11,236 · MeSH hits: 0
Who's working on it?
1,237
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Johnson NE12 papers · 2026
Department of Neurology, Richmond Commonwealth University, Richmond, USA.
Papers in Europe PMC - 02Gagnon C11 papers · 2026
Interdisciplinary Research Group on Neuromuscular Diseases (GRIMN), Integrated University Health and Social Services Centre of Saguenay-Lac-Saint-Jean, Saguenay, QC, Canada.
Papers in Europe PMC - 03Thornton CA8 papers · 2026
Department of Neurology, University of Rochester Medical Center, NY.
Papers in Europe PMC - 04Gourdon G7 papers · 2026
Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
Papers in Europe PMC - 05Mul K7 papers · 2026
Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud Research Institute for Medical Innovation, Nijmegen, The Netherlands.
Papers in Europe PMC - 06Schoser B7 papers · 2026
Friedrich-Baur-Institute, Dep. of Neurology LMU Clinic, Munich, Germany.
Papers in Europe PMC - 07Artero R6 papers · 2026
CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain.
Papers in Europe PMC - 08Bassez G6 papers · 2026
Neuromuscular Reference Centre, Pitiè-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.
Papers in Europe PMC - 09Chahine M6 papers · 2026
CERVO Brain Research Centre, Quebec City, QC, Canada; Department of Medicine, Faculty of Medicine, Université Laval, Quebec City, QC, Canada. Electronic address: mohamed.chahine@phc.ulaval.ca.
Papers in Europe PMC - 10Eichinger K6 papers · 2026
Department of Neurology, University of Rochester Medical Center, NY.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
45
interventional trials for this specific condition
45 interventional trials matched this specific condition name; 16 currently recruiting in our sample. 20 trials are registered for myotonic dystrophy, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 28 July 2026
45 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 97th percentile).
medium confidence · 97th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
45 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06708468·RECRUITING·Personalized Training for People With Rare Neuromuscular Disorders
Not reviewed·Conditions: Neuromuscular Diseases (NMD) · Charcot Marie Tooth Disease (CMT) · Facioscapulohumeral Muscular Dystrophy · Myotonic Dystrophy Type 1 (DM1)·Matched via name phrase
- NCT07008469·ENROLLING BY INVITATION·Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
Not reviewed·Conditions: Myotonic Dystrophy Type 1 · DM1 · Myotonic Dystrophy · Myotonia·Matched via name phrase
- NCT06316778·RECRUITING·Pelvic Floor Muscle Training for Women with Myotonic Dystrophy
Not reviewed·Conditions: Myotonic Dystrophy Type 1 · Urinary Incontinence·Matched via name phrase
- NCT06926621·ENROLLING BY INVITATION·A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
Not reviewed·Conditions: Myotonic Dystrophy Type 1 (DM1)·Matched via name phrase
- NCT05481879·RECRUITING·Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
Not reviewed·Conditions: Myotonic Dystrophy Type 1 (DM1)·Matched via name phrase
- NCT06523400·RECRUITING·The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
Not reviewed·Conditions: Myotonic Dystrophy·Matched via name phrase
- NCT07220603·RECRUITING·An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
Not reviewed·Conditions: Myotonic Dystrophy 1·Matched via name phrase
- NCT07486934·RECRUITING·Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Not reviewed·Conditions: Myotonic Dystrophy Type 1 (DM1) · DM1 · Myotonic Dystrophy · Steinert Disease·Matched via name phrase
- NCT06596850·NOT YET RECRUITING·Wheelchair Skills Training for People with ARSACS and DM1
Not reviewed·Conditions: Wheelchair Mobility · Manual Wheelchair Skills Training · ARSACS · Myotonic Dystrophy Type 1·Matched via name phrase
- NCT06667453·RECRUITING·A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
Not reviewed·Conditions: Myotonic Dystrophy 1·Matched via name phrase
- NCT07415837·RECRUITING·Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies
Not reviewed·Conditions: Duchenne / Becker Muscular Dystrophy · Dystrophia Myotonica 1 · Congenital Myopathies · Healthy Participants·Matched via name phrase
- NCT06549400·ENROLLING BY INVITATION·An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
Not reviewed·Conditions: Myotonic Dystrophy·Matched via name phrase
- NCT06844214·RECRUITING·A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1
Not reviewed·Conditions: Myotonic Dystrophy·Matched via name phrase
- NCT05532813·RECRUITING·Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
Not reviewed·Conditions: Steinert's Disease · Myotonic Dystrophy 1 · Metformin·Matched via name phrase
- NCT07075965·NOT YET RECRUITING·Calcium Channel Blocker in Myotonic Dystrophy Type 1
Not reviewed·Conditions: Myotonic Dystrophy 1·Matched via name phrase
Broader category: myotonic dystrophy
20
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07072676·ENROLLING BY INVITATION·The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
Not reviewed·Conditions: Inclusion Body Myositis · Myotonic Dystrophy 1 · Myotonic Dystrophy 2 · Facio-Scapulo-Humeral Dystrophy·Matched via name phrase
- NCT07136844·RECRUITING·Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
Not reviewed·Conditions: Neuromuscular Diseases · Obesity (Disorder) · Myotonic Dystrophy 1 · Myasthenic Syndrome·Matched via name phrase
- NCT06716931·RECRUITING·Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)
Not reviewed·Conditions: Myotonic Dystrophy 2·Matched via name phrase
- NCT07321977·RECRUITING·Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers
Not reviewed·Conditions: Spinal Muscular Atrophy (SMA) · Charcot-Marie-Tooth · Muscular Dystrophy · Myotonic Dystrophy·Matched via name phrase
- NCT05004129·RECRUITING·Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Not reviewed·Conditions: Congenital Myotonic Dystrophy·Matched via name phrase
- NCT05982119·RECRUITING·Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study
Not reviewed·Conditions: Duchenne Muscular Dystrophy · Fascioscapulohumeral Muscular Dystrophy · Myotonic Dystrophy 1 · Charcot-Marie-Tooth·Matched via name phrase
- NCT06300307·RECRUITING·Study of ATX-01 in Participants With DM1
Not reviewed·Conditions: Myotonic Dystrophy 1·Matched via name phrase
- NCT06138743·RECRUITING·Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy
Not reviewed·Conditions: Myotonic Dystrophy 1·Matched via name phrase
- NCT07608432·RECRUITING·Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
Not reviewed·Conditions: Duchenne Muscular Dystrophy (DMD) · Muscular Dystrophy, Duchenne · Muscular Dystrophy (DMD) · DMD·Matched via name phrase
- NCT07587242·NOT YET RECRUITING·A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
Not reviewed·Conditions: Muscular Dystrophies · Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy) · Muscular Disorders, Atrophic · Muscular Disease·Matched via name phrase
Observational and natural-history studies
27 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07700225·RECRUITING·Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Not reviewed·Conditions: DM1 · Myotonic Dystrophy · Myotonic Dystrophy 1 · Myotonic Dystrophy Type 1·Matched via name phrase
- NCT07505342·RECRUITING·Remote Assessments and Genetic Determinants of Myotonic Dystrophy
Not reviewed·Conditions: Myotonic Dystrophy Type 1 (DM1) · DM1·Matched via name phrase
- NCT06101940·ENROLLING BY INVITATION·Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (C-DMCOS-DM1)
Not reviewed·Conditions: Myotonic Dystrophy 1·Matched via name phrase
- NCT06979024·ENROLLING BY INVITATION·A Registered Observational Cohort Study of Myotonic Dystrophy Type 1
Not reviewed·Conditions: Myotonic Dystrophy Type 1 (DM1)·Matched via name phrase
- NCT03981575·RECRUITING·Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Not reviewed·Conditions: Myotonic Dystrophy 1 · DM1·Matched via name phrase
- NCT06813443·RECRUITING·Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation
Not reviewed·Conditions: Cardiomyopathies · Amyloidosis Cardiac · Fabry Disease · Arrhythmogenic Cardiomyopathy·Matched via name phrase
- NCT07630389·RECRUITING·Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy
Not reviewed·Conditions: Myotonic Dystrophy Type 1 · Congenital DM1 · Juvenile DM1 · Childhood DM1·Matched via name phrase
- NCT00082108·RECRUITING·Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Not reviewed·Conditions: Myotonic Dystrophy · Facioscapulohumeral Muscular Dystrophy · Muscular Dystrophy · Myotonic Dystrophy Type 1·Matched via name phrase
- NCT02398786·RECRUITING·Myotonic Dystrophy Family Registry
Not reviewed·Conditions: Myotonic Dystrophy · Congenital Myotonic Dystrophy · Myotonic Dystrophy 1 · Myotonic Dystrophy 2·Matched via name phrase
- NCT05854433·ENROLLING BY INVITATION·Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2
Not reviewed·Conditions: Myotonic Dystrophy Type 2 · Myotonic Dystrophy Type 1·Matched via name phrase
- NCT06075693·RECRUITING·Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
Not reviewed·Conditions: Myotonic Dystrophy Type 1·Matched via name phrase
- NCT07385443·RECRUITING·The Spanish National Registry for Myotonic Dystrophy Type 1
Not reviewed·Conditions: Myotonic Dystrophy 1 · DM1 · Myotonic Dystrophy Type 1 · Myotonic Dystrophy, Congenital·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 15 · after dedupe 15 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 15 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (15)
- ctis·2025-522957-20-00·Authorised, ongoing·A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1
skipped — LLM skipped (--skip-llm)
- ctis·2025-520766-22-00·Authorised, recruiting·A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
skipped — LLM skipped (--skip-llm)
- ctis·2024-517983-47-00·Authorised, ongoing·An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects with Myotonic Dystrophy Type I
skipped — LLM skipped (--skip-llm)
- ctis·2024-511178-66-00·Authorised, ongoing·An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients with Myotonic Dystrophy Type 1 and Type 2 who have completed the MEX-DM-302 Study.
skipped — LLM skipped (--skip-llm)
- ctis·2024-511179-13-00·Authorised, ongoing·A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients with Myotonic Dystrophy Type 1 and Type 2
skipped — LLM skipped (--skip-llm)
- ctis·2024-511378-60-00·Expired·A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
skipped — LLM skipped (--skip-llm)
- ctis·2023-505363-37-00·Authorised, ongoing·A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of Intravenous Administration of ATX-01 In Male and Female Participants aged 18 to 64 with Classic Myotonic Dystrophy Type 1 (DM1)
skipped — LLM skipped (--skip-llm)
- ctis·2023-507660-39-00·Authorised, ongoing·EVALUATION OF THE EFFICACY AND SAFETY OF METFORMIN IN THE MYOTONIC DYSTROPHY TYPE I (STEINERT’S DISEASE). PHASE III PROSPECTIVE, MULTICENTRE, RANDOMISED, DOUBLE-BLIND CONTROLLED STUDY.
skipped — LLM skipped (--skip-llm)
- ctis·2023-510353-42-00·Expired·A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1
skipped — LLM skipped (--skip-llm)
- ctis·2023-506028-10-00·Authorised, ongoing·A Phase 1/2, Randomized, Double-blind, Placebo‑controlled Single- and Multiple‑dose Escalation Study Evaluating the Safety, Tolerability,
Pharmacokinetics, and Pharmacodynamics of VX‑670 in Adult Subjects with Myotonic Dystrophy Type 1
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN79964452·Recruiting·A phase I trial of DT-818 in healthy volunteers and adults with myotonic dystrophy type 1
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16491505·No longer recruiting·The evaluation of heart muscle changes in muscular dystrophies applying cardiac magnetic resonance: follow-up study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN81917128·No longer recruiting·The high-resolution three-dimensional magnetic detector system 3D-MAGMA accurately measures gastric and small bowel motility in people with type 2 diabetes with neuropathy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN59243785·No longer recruiting·A clinical investigation of a novel functional electrical stimulation system
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16419921·No longer recruiting·The survival and quality of life benefits of melatonin when administered to cancer patients at the optimal time of day
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Steinert myotonic dystrophy — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Steinert myotonic dystrophy" OR "Myotonic dystrophy type 1" OR "Steinert disease" OR "DMPK myotonic dystrophy" OR "Steinert myotonic dystrophy syndrome" OR "Steinert syndrome" OR "dystrophia myotonica" OR "myotonic dystrophy caused by mutation in DMPK") OR ("DMPK" OR "DMPK syndrome" OR "DMPK-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Steinert myotonic dystrophy" OR "Myotonic dystrophy type 1" OR "Steinert disease" OR "DMPK myotonic dystrophy" OR "Steinert myotonic dystrophy syndrome" OR "Steinert syndrome" OR "dystrophia myotonica" OR "myotonic dystrophy caused by mutation in DMPK"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 45 interventional · 27 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"myotonic dystrophy"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: DM1; MD1
Confidence reasoning
- Preferred label is multi-word and distinctive
- 2 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T13:09:56.536Z
